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A glycoprotein that inhibits complement activation is present on the surface
ofhuman erythrocytes (Eh°)' (1-3) . This -70 kD surface component (3), termed
decay-accelerating factor (DAF), interacts with autologous C4b and C3b that
inadvertantly become associated with Eh° and prevents the covalently bound
fragments from serving as sites for the uptake and conversion of C2 and factor
B into enzymatically active C2a and Bb (4, 5) . The interference by DAF with
these C4b- and C3b-dependent cleavages prevents the assembly of C3 and C5
convertases of both complement pathways, i.e ., all amplifying enzymes of the
complement cascade (5) . Unlike the serum regulatory proteins, C4 binding
protein (C4bp) and factor H, which interact extrinsically with convertases on
targets of complement (e.g ., microorganisms or immune complexes), DAF acts
only within the surface of the same cells, i.e ., it is strictly an intrinsic membrane
inhibitor (5) . The ability of DAF to move freely in the plane of host Ehu
membranes and efficiently restrict formation of autologous amplification con-
vertases on their surfaces protects Eh° from injury that could arise from C4b or
C3b deposited directly, e.g ., via autoantibody, or in a bystander fashion as a
result of complement activation in their vicinity .
Studies using flow cytometry and radioimmunometric assays based on anti-
DAF antibodies (6, 7) have shown that DAF is present not only on the surface
of Eh° but also in the membranes of circulating neutrophils, monocytes, B andT
lymphocytes, and platelets, as well as on vascular endothelium (8), all cell types
that are in intimate contact with serum complement proteins . In blood cells,
DAF levels are highest in neutrophils and monocytes, cell types that interact
closely with complement-bearing targets during the events that preceed their
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' Abbreviations used in this paper:
￿
A, rabbit hemolysin ; AChE, acetylcholinesterase ; Az, azide ;
C4bp, C4 binding protein ; DAF, decay-accelerating factor ; Eh", human erythrocytes ; E'h, sheep
erythrocytes ;GVB`, veronal buffer with gelatin ; mfVSG, membrane form variant surface glycopro-
teins; PNH, paroxysmal nocturnal hemoglobinuria ; PPO, 2,5-diphenyloxazole ; PI-PLC, phosphati-
dylinositol-specific phospholipase-C ; SFU, site forming unit ; sVSG, soluble form ofVSG.
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ingestion (6). Incorporation of exogenous DAF in vitro into affected Et'° of
patients with paroxysmal nocturnal hemoglobinuria (PNH) (9), a disorder in
which DAF is deficient (4, 6, 10-12), diminishes the exaggerated uptake of C3b
that characterizes the complement-sensitive PNH Eh" in vivo (reviewed in refer-
ence 13). These findings that DAF deficiency is causally involved in the comple-
ment sensitivity of affected PNH cells have established that DAF activity in blood
cells is essential under physiological conditions.
The present study was undertaken to investigate the distribution of DAF
outside the vascular space.
Materials and Methods
Proteins, Antibodies, and Radiolabeling.
￿
El" DAF was purified from NP-40 extracts of
stroma as described (5). The product appeared homogeneous upon analysis by SDS-PAGE
and silver staining (see Fig. 1 of reference 5). Guinea pig C1 (14) and C3-9 (14) and
human C4 (15), C2 (16), and C4bp (17) were purified as described. Murine anti-human
DAF mAbs IAIO, IIH6, and VIIIA7 (6); anti-human C3b/C4b receptor (CR1) mAbs
57F, 4413, and 3113 (18); and antimalaria mAbs 2133, 2A10, 31311, and 6G2 (19) were
obtained as described. Each was purified from ascites fluid by ammonium sulfate precipi-
tation, DEAE-Sephacel chromatography, and Sephadex G200 gel filtration. Peroxidase-
labeled goat anti-murine Ig (affinity purified, IgG and IgM H and L chain specific) was
purchased from Kirkegaard & Perry Laboratories, Inc. (Gaithersburg, MD). Protein A-
Sepharose was from Pharmacia Fine Chemicals (Piscataway, NJ).
Proteins and antibodies were labeled with
1251 using Iodogen (Pierce Chemical Co.,
Rockford, IL) according to the manufacturer's instructions. Iodinated products were
purified by gel filtration followed by extensive dialysis.
Immunohistochemical Studies.
￿
Autopsy tissues and corneas (Oregon Lions Eye Bank,
Portland, OR) preserved in RPMI medium were placed in OCT compound (Miles
Laboratories Inc., Naperville, IL) and snap frozen. Cryostat tissue sections were fixed by
sequential immersion for 2 min in cold acetone and 7 min in acetone/chloroform (1 :1).
After drying and washing three times with 150 mM NaCl, 10 mM sodium phosphate, pH
7.4 (PBS), the fixed sections were overlayered with a predetermined optimal concentration
(see Results) of pooled anti-DAF mAbs (IA 10, IIH6, and VIIIA7) in PBS containing 10%
goat serum or with corresponding amounts ofpooled anti-CR 1 mAbs (57F, 4413, 31 D) or
nonrelevant antimalaria mAbs (2133, 2A10, and 31311) of the same subclasses in the same
buffer. The antibody-treated sections were incubated in a moist chamber at 200 C for I
h, and after thorough washing three times in PBS, they were overlayered a second time
with a 1 :40 dilution in PBS of peroxidase-labeled goat anti-murine Ig antibody. After
another incubation at 20 ° C for 30 min and a second thorough washing in PBS, the
sections were stained by immersion for 10 min in 50 ml of PBS containing 500 wl of 3,3'-
diaminobenzidine and 150 gl of 3% hydrogen peroxide. Stained sections were washed in
PBS, counterstained for 90 s with hematoxylin, and after extensive washing with cold
water and dehydration by baths in absolute ethanol and xylene, they were mounted in
Permount.
Affinity Purification ofUrineDAF.
￿
Fresh urine voidings were individually collected into
500-ml polystyrene bottles containing 5 ml of 100 mM PMSF, 100 Ag/ml leupeptin, 1 .2
mg/ml soybean trypsin inhibitor, 100 kg/ml aprotinin, 200 mM benzamidine, 500 mM
EDTA, and 0 .5% sodium azide, and after mixing were immediately frozen at -70'C.
When sufficient numbers of bottles from a given individual (usually 8-10) were accumu-
lated, they were simultaneously thawed, their contents pooled, and the pooled urine was
concentrated to 10% of the original volume in an Amicon Corp. (Danvers, MA) DC-2
hollow fiber apparatus equipped with an HIP30 cartridge. After dialysis against 150 mM
NaCl, 25 mM Tris, 20 mM EDTA, pH 7.4 and clarification by centrifugation at 10,000
g for 60 min, the urine concentrate was applied to an affinity column composed of anti-
DAF mAb IA 10 coupled to CNBr-Sepharose and crosslinked with glutaraldehyde (^-100850
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ml concentrate/5 mg antibody) that waspreequilibrated in thesame buffer. Afterloading,
the column was washed with 10 volumesof 0.5 M NaC1, 25 mM Tris, 20 mM EDTA, pH
7.4 and then eluted with 0.05 M diethylamine, 140 mM NaCI, pH 11 .5 (20) . Column
fractions(usually 0.5 ml) were immediately neutralized by collection into tubescontaining
0.1 ml of 1.0 M Tris, pH 6.0, saturated with glycine. Each fraction was assayed for DAF
antigen by two-site radioimmunometric assay (see below) and positive fractions were
examined by SDS-PAGE and silver staining. Urine DAF-containing fractions that were
free of protein contaminants were pooled, dialyzed against PBS, and frozen in aliquots at
-70°C. Overall yield varied from 20-100 wg urine DAF/L urine. The product gave a
single band on Western blots developed with anti-DAF monoclonals and on autoradi-
ographs after SDS-PAGE of the '25Habeled product.
Radioimmunometric and Hemolytic Assays.
￿
Quantitations of DAF concentrations by two
site radioimmunometric assay were performed as described in (6). Briefly, samples and
DAF standards were added in duplicate 25-Al aliquots to the wells of 96 well U-bottomed
plastic microtiter plates (Becton Dickinson & Co., Oxnard, CA) precoated for 2 hat 20 °C
with 50 wl of 20 ug/ml anti-DAF mAb IA 10 and the wells were blocked with PBS
containing 1% BSA. After incubation at 20°C for 2 h and washing three times with the
blocking buffer containing 0.05% Tween-20, 25 Al of '21I-labeled anti-DAF mAb IIH6
(containing -10-' cpm) was added, and after further incubation at 20°C for 1 h and
extensive washing, bound DAF antigen in the samples was quantitated by comparison of
counts in cut-outwells that received samplesto those in wellsth4t received DAF standards.
Hemolytic assays were performed as described (5) using complement intermediates
prepared from sheep erythrocytes (E'h) sensitized with 300 site forming units (SFU) of
rabbit hemolysin (A) per cell. EAAC14 were prepared by incubating E"A sequentially
with 300 SFU of guinea pig C1 and 10 SFU of human C4. E'hAC142 were prepared by
incubating the resulting E° AC14 with sufficient human C2 to yield cells bearing one
hemolytic site of C4b2a after washing and decay for 15 min at 30°C. Incubations of
EshAC142 with Eh" DAF and urine DAF were performed at 30°C in 145 mM NaCl, 2.5
mM veronal, pH 7.3, containing 0.5 mM MgC12, 0.1 mM CaCl2, and 0.1 % gelatin(GVB2+).
C4 hemolytic sites were quantitated by incubation of E"'AC14 with 300 SFU of C2
followed by 300 SFU of guinea pig C3-9 and C4b2a sites developed by direct incubation
of E`AC142 with 300 SFU of guinea pig C3-9.
SDS-PAGE and Western Blotting.
￿
SDS-PAGE was conducted on 7.5% linear slab gels
according to the method of Laemmli (21). Gels of 3'S-labeled samples were washed with
DMSO and treated with 2,5-diphenyloxazole (PPO) followed by water before drying.
Autoradiography and fluorography were performed at -70'C on X-Omat XAR-5 film
(Eastman Kodak Co., Rochester, NY).
For Western blots, proteins were subjected to SDS-PAGE on 7.5% gels under nonre-
ducing conditions. The separated proteins were transferred to nitrocellulose using a
Transblot Apparatus (Bio-Rad Laboratories, Richmond, CA). After blocking for 1 h at
37°C with PBS containing 5% BSA and 0.05% azide (AZ) (PBS-BSA-AZ), nitrocellulose
strips were incubatedat 20°C for 1 h with "'I-labeled anti-DAF mAb IIH6, washed three
times with PBS-BSA-AZ, dried, and loaded into film cassettes.
Preparation of Cell Extracts and Immunoprecipitation.
￿
For radioimmunometric assays,
cell monolayers were washed with PBS and extracted for 20 min at 0°C with 50 A,1/106
cells of 0.5% NP-40 in PBS containing 1 mM PMSF and 5 mg/ml synthetic elastase
inhibitor[Suc-(OMe)-Ala-Ala-Pro-Val-MCA] (Peninsula Laboratories, Inc., Belmont, CA).
The NP-40 extracts were centrifuged at 12,000 g for 15 min and the supernatant was
transferred to new tubes. For SDS-PAGE and Western blot analyses, cell monolayers were
scraped from culture dishes with 2% SDS in 20 mM Tris, pH 7.5, 100 IA/ml trasylol (250
,1/106 cells) usinga rubber policeman. The SDS extracts were boiled for 10 min, diluted
fivefold with 50 mM Tris, pH 7.4, containing 190 mM NaCl, 100 A/ml trasylol, 6 mM
EDTA, and 2.5% Triton X-100 (Tris-NaCI-EDTA), the mixture was centrifuged at
10,000 gfor 15 min, and the supernatant was transferred to a new tube.
Samples of SDS-cell extracts (usually 600 Al) or of extracellular fluids or culture
supernatants (200-4,000 ,,1) were preabsorbedfor 2 h at 20 °C with 100,u] of 10% ProteinMEDOF ET AL.
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A-Sepharose in Tris-NaCl-EDTA and were centrifuged. Supernatants were transferred
to new tubes, pooled anti-DAF mAbs IA10, IIH6, and VIIIA7 (5 ug/ml each) or
nonrelevant antimalaria mAbs (of the same subclasses, 5 F.g/ml each) were added, and the
mixtures were rotated for 2 h at 20°C. Immune complexes were precipitated by addition
of 100 kl of fresh 10% Protein A-Sepharose in Tris-NaCI-EDTA buffer, further rotation
for 1 h at 20'C, and centrifugation. The beads were transferred to new tubes, washed
twice with Tris-NaCl-EDTA buffer, and immunoprecipitated proteins were extracted by
addition of 50 ul of SDS-PAGE sample buffer followed by boiling for 3 min.
Biosynthetic Studies.
￿
Biosynthetic labeling was performed as described (22). Semicon-
fluent (60-70%) HeLa cell monolayers were prepared in 60-mm culture plates. The cells
were preincubated for 1 h before labeling with cysteine (Cys)-free RPMI containing 10%
dialyzed FCS. [s5S]Cys (50 pCi; New England Nuclear, Boston, MA) was added in 100-kl
aliquots to replicate plates. The plates were placed at 37°C, and after various times, the
plates were transferred to ice, the medium was removed, and the cells were extracted
with 2% SDS in Tris buffer as described above.
Results
Expression ofDAF 6y Epithelial Cells.
￿
To determine whether DAF is expressed
by cell types other than those in the vascular space, immunohistochemical analyses
of various tissues were performed with anti-DAF mAbs. Since B lymphocytes
express 7 X 104 DAF molecules per cell (6), initial studies were carried out with
lymph node specimens to establish optimal conditions for the detection of DAF
in tissue sections. Sections of the lymph nodes (fixed as described in Materials
and Methods) were incubated with serial dilutions of pooled anti-DAF monoclo-
nals, corresponding dilutions of pooled anti-CR1 mAbs, or with nonrelevant
(antimalaria) mAbs as controls. After washing and development with peroxidase-
labeled goat anti-mouse Ig (see Materials and Methods), the sections were
examined by light microscopy. Bright anti-DAF staining of germinal center
lymphocytes was observed after treatment of the sections with 250 ng/ml of
pooled anti-DAF mAbs, while no staining was observed with 10 ug/ml of
nonrelevant mAbs. The anti-DAF staining was most intense in lymphocytes also
stained by anti-CR1 mAbs (100 ng/ml) but was also apparent in lymphocytes
that were anti-CRI-negative.
Samples of different tissues were next collected from surgical and autopsy
specimens, frozen sections of the specimens were fixed and stained, and the
sections were examined as described above for the lymph nodes. Selected
photographs of the results are shown in Figs. 1 and 2 . Unexpectedly, strong anti-
DAF staining ofepithelial cells in multiple locations was observed. The anti-DAF
staining of epithelium was striking in cornea (Fig. 1 A), conjunctiva (Fig. 1 B),
oral mucosa and salivary glands (Fig. 1 C), esophagus (Fig. 2A), upper and lower
GI tract (not shown), and in kidneys and urinary tract (not shown). The anti-
DAF staining was also prominent in endocardium (not shown), synovial cells
(Fig. 2B) lining joint spaces, and in endometrial and epithelial cells lining uterus
(Fig. 2C) and cervix (not shown). In kidneys, epithelium was positive in proximal
tubules, descending and ascending loops of Henle and in collecting ducts. In
contrast to previously reported findings (23, 24) and control studies with anti-
CR1 antibodies, anti-DAF staining in renal cortex was not localized to glomeruli
(podocytes) but was diffuse. In the urinary tract, urethelium was strongly positive
in medullary spaces, ureter, bladder, and urethra (not shown). In all sites with
layered epithelium, intensity of anti-DAF staining increased with cell maturation852 BODY FLUID DECAY-ACCELER
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and staining was greatest in epithelial margins and on surfaces.
In addition to the epithelial cell staining, intense anti-DAF positivity of exocrine
gland cells in many sites (Figs. 1, B and C; 2 A) was apparent and strong anti-
DAF staining within extracellular matrix in several tissues (Figs. 1 B; 2, A and C)
was noted. As observed with epithelial cells, the intensity of anti-DAF staining of
glandular cells increased with cell maturation. The anti-DAF staining within
extracellular matrix consistently occurred in a fibrillar pattern . The fibrillar
staining was prominent in fibrous sheaths surrounding myocardial muscle bun-
dles, interstitium underlying endocardium, and connective tissue adjacent to
synovium (Fig. 2B). The nature of the fibrils is unknown. Patterns of anti-DAF
staining of epithelium, glandular cells, and connective tissue similar to those
shown (in Figs. 1 and 2) were also observed in pleura, pericardium, and perito-
neum.
Soluble DAF Forms in Extracellular Fluids.
￿
The possibility that DAF antigen
might be present in extracellular fluids adjacent to epithelial cell surfaces sur-
rounding various extracellular compartments was next investigated. Samples of
different extracellular fluids were obtained and the specimens were assayed for
DAF antigen by two-site radioimmunometric assay using anti-DAF mAbs.
The results of analyses of tears, saliva, synovial fluid, cerebrospinal fluid, and
of plasma are summarized in Table 1. DAF antigen was present in all fluids
tested, and the concentrations were in most instances greater than that in plasma.
Measurements of DAF in urine samples collected from 10 normal individuals
are given in Table 11 . 75-500 ng/ml of antigen was found in spot specimens.
Quantitations of antigen in 24-h urine collections revealed outputs as high as
500 gg, a value corresponding to ^-3% of the total intravascular blood cell-
associated membrane DAF.
To study the nature of DAF antigen present in the body fluids, the antigens
detected in tears, saliva, and urine were precipitated with anti-DAF mAbs and
examined on Western blots. The antigens in tears and saliva migrated with
apparent M, higher (>100,000) (not shown) than Eh°DAF, while that in urine
migrated with a slightly lower M,. (^-67,000) (see below). The more abundant
urine antigen was isolated for further structural and functional investigations.
Large volumes (^-5 liters each) of urine from six normal individuals were collected
into vessels containing multiple protease inhibitors. The six urine collections
were separately concentrated, and the DAF antigen in each purified by affinity
chromatography and compared by Western blot analysis (Fig. 3A). In all cases,
the urine DAF variant was ^-3 kD smaller than membrane DAF isolated from
Eh".
Urine DAF from one individual (Fig. 3A, lane 1) was next tested in complement
assays for functional activity and its regulatory properties were compared to
those of Eh" membrane DAR Unlike purified Eh"DAF, which incorporated into
EShAC 14 and markedly inhibited C4 hemolytic activity on washed EShAC 14
intermediates (Fig. 3B), the urine DAF had little activity in this assay. However,
when the urine molecule was incubated in the presence of E$hAC 142 bearing
preformed C4b2a, it accelerated C4b2a decay with an efficiency comparable to
that of serum C4bp. The decay-accelerating effect was blocked by addition of
pooled anti-DAF mAbs. A simple interpretation of these findings is that urine* Osteoarthritis.
Evaluation for headache.
MEDOF ET AL.
￿
855
TABLE I
DAF Levels in Body Fluids
TABLE II
Levels ofUrine DAF in Normal Individuals
DAF is unable to incorporate into cell membranes and therefore cannot exert
its effect intrinsically. Indeed, urine DAF is less hydrophobic than membrane
DAF. When subjected to chromatography on Phenyl-Sepharose beads, all of the
membrane DAF bound tightly to the resin, while the urine molecule remained
>90% in the fluid phase, indicating that it differs markedly with respect to
hydrophobicity (not shown).
Appearance of a Soluble DAF Form Resembling Urine DAF from HeLa Cell and
Foreskin Epithelium Culture Supernatants.
￿
In view of the concurrent findings of
high levels of DAF expression by epithelial cells and the presence ofsoluble DAF
forms in adjacent body fluids, in vitro studies were next performed to investigate
the possible epithelial cell origin of the extracellular DAF species. For this
purpose, human foreskin epithelium and the HeLa epithelial cell line were
cultured.
FIGURE 2.
￿
(A) Anti-DAF staining of esophageal mucosa is evident. Prominent staining of
glands and fibers in underlying submucosal connective tissue additionally can be appreciated.
(B) Localized anti-DAF staining of synoviocytes and fibers is observed. Staining of fibers is
again appreciated. (C) The staining of fibers underlying uterine endometrium is prominent.
Donor
RW
DAF
ng/ml
150
Volume
ml/24 h
1,000
Total DAF
jug/24 h
150
AC 170 1,700 290
RC 127 1,600 200
RR 100 3,200 320
VN 200 2,550 510
AF 250 1,400 550
MD 350 1,200 420
RM 400 1,200 480
EW 75 1,700 128
SK 75 2,450 185
DE 200 1,200 240
Mean 298
Fluid Number of
samples
DAF concentration
± SD
ng/ml
Plasma 12 64 ± 26
Saliva 9 112 i 51
Tears 2 344, 68
Synovial fluid 8* 168 ± 99
Cerebrospinal fluid 1t 38856
￿
EPITHELIAL AND BODY FLUID DECAY-ACCELERATING FACTOR
EAC14(Urine DAF)+C2
[DAF] or [urine DAF] ng/ml
FIGURE 3.
￿
Comparison of the gel mobilities and functional properties of urine DAF and Eh'
membrane DAF . (A) Urine DAF samples were immunopreci~itated from urine concentrates
prepared from six normal individuals and compared with E " membrane DAF on Western
blots after electrophoresis of proteins on 7.5% SDS-PAGE gels undernonreducing conditions .
In the case ofall six urine DAF isolates a single band ^-3,000 smaller in apparent M, than Eh"
membrane DAF was observed . M, X 10' shown at left. (B) Purified urine DAF and Eh"
membrane DAF were incubated with E'hAC14, and after washing, residual C4b sites were
developed by addition of C2 and C3-9 . Alternatively, the urine DAF was incubated for 15
min at 30"C with E'hAC142 and remainingC4b2a sites were assayed by addition of C3-9 . A
control using urine DAF in the presence of anti-DAF mAbs was performed (not shown) .
UnlikeEh" membrane DAF, the urineDAFhadno effect onE'AC 14 but it inhibited hemolytic
activity ofpreformed C4b2a with efficiency comparable to C4bp,
As shown in Fig. 4, immunohistochemical analyses of both cultured cell types
showed strong anti-DAF staining . Immunoradiometric assays of the HeLa cell
extracts revealed ^-2X 105DAF moleculesper cell, approximately fourfold more
DAF than present in polymorphonuclear leukocytes (6). Purification of HeLa
cell DAF by immunoprecipitation with anti-DAF mAbs and Western blot analyses
of the immunoprecipitate demonstrated that the HeLa epithelial cell DAF was
similar in apparent size (M,. ^"72,000) to blood mononuclear cell membrane DAF
(see reference 6).FIGURE 4.
￿
Human foreskin epithelium and the HeLa cell line were cultured . lmmunolIisto-
chemical analyses ofthe cultured cellsshowed strong anti-DAF staining (A) . Immunoradiomet-
ric assays of the HeLa cell extracts revealed -2 X 10' membrane DAF molecules per cell . (B)
Fluorographs of a continuous labeling study ofDAF biosynthesis in HeLa cells . After a 1-h
tion with Cys-free RPNH and labeling with ["S]Cys for the time periods shown, the
ionola rs were extracted with SDS and newly labeled DAF proteins were isolated by
immunoprecipitation and analyzed by SDS-PAGE/fluorography. The lanes designated
show the resultsofcontrol studies with norrelevantmAbs.M . X 10' shown at left .
MEDOF ET AL.
￿
857
HeLa cells were next cultured, and during log phase growth, the culture
was analyzed at different times by radioimmunometric assay for
tigen . The results showed a progressive accumulation of the antigen in
culture medium (Fig . 5) . In contrast, no DAF antigen was detectable in the
supernatant of K562 erythroleukem
La cells were next cultured for various times in the presence of t"S]Cys
and newly synthesized DAF in the membranes of the cells and in the culture858
￿
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K562
900 1200
Time in minutes
FIGURE 5.
￿
HeLa cells were cultured, and during log phase growth, the culture supernatant
wasassayed at different times for DAF antigen by radiometric assay. While no DAFantigen
wasdetectable in the supernatant of DAF-containing (4 X 106 cells/ml)K562 erythroleukemia
cells, progressively increasing levels of DAF antigen were measurable in the HeLa cell (2 X
106 cells/ml) supernatants.
600
supernatant were isolated by specific immunoprecipitation and analyzed by SDS-
PAGE/radioautography . In addition to mature 72 kD HeLa membrane DAF
and a 48 kD intracellular DAF precursor (22), a DAF species with apparent M,
5,000 smaller than the mature membrane molecule was isolated from the cells.
The larger but not the smaller DAF species was detectable on autoradiographs
of SDS-PAGE gels ofanti-DAF immunoprecipitates of 1251 surface-labeled HeLa
cells. A DAF molecule of comparable size to the smaller DAF species was
recovered from the culture supernatant (not shown). When examined next to
urine DAF on Western blots, this 67 kD DAF molecule appeared similar in gel
mobility.
Discussion
In previous studies, we and others showed that DAF is present on the surface
of blood cells (6, 7) and vascular endothelium (8) where its activity is essential to
protect these cell types from serum complement proteins. In the present study,
the investigated the distribution of DAF in tissues and body fluids outside the
vascular space. Immunohistochemical analyses revealed large amounts of DAF
antigen on the surface of epithelium in multiple sites and radioimmunometric
assays identified soluble forms of the antigen in several extracellular fluids .
Purification of the most abundant extracellular DAF form, urine DAF, and
analyses of its properties demonstrated that, like Eh° membrane DAF, it possessed
C4bp-like complement regulatory activity. Unlike Eh° DAF, however, it was
unable to incorporate into membranes and on SDS-PAGE appeared ^-3 kD
smaller in apparent size. Studies using primary cultures of foreskin epithelium
and the epithelial cell line HeLa demonstrated de novo biosynthesis of DAF
protein in amounts greatly exceeding those in blood cells. Analyses of the culture
supernatants of these studies disclosed the release by these cell types of a soluble
DAF form closely resembling urine DAF in SDS-PAGE gel mobility.
In our immunohistochemical analyses, epithelial cells stained brightly for DAF
in all locations where surface epithelium is found. These included cornea,
conjunctiva, oral and gastrointestinal mucosa, renal tubular epithelium and
urinary tract urethelium, uterine endometrium and cervical epithelium, pleural
and pericardial serosa, and synoviocytes lining diarthrodial joint spaces. InMEDOF ET AL.
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addition to the anti-DAF staining ofthese surface cells, strong anti-DAF staining
of exocrine glandular cells was observed throughout many tissues. In the case of
both surface epithelium and glandular cells, intensity of anti-DAF staining
increased in cells closest to the surface. Within glands, the most intense staining
was observed in lumens. The increase could represent induction ofDAF expres-
sion with cell differentiation/maturation. In vitro studieswith epithelial cell lines
(reviewed in reference 25) have shown that expression of certain membrane
proteins is polarized to the nonadherent exterior cell surface.
The physiologic function that DAF serves on epithelial and glandular cell
surfaces is not yet apparent. The principal secretory immunoglobulin is IgA and
it can only activate the alternative pathway of complement. However, other
immunoglobulins, e.g., IgM, are found in smaller amounts in secretions, as are
complement components (26). The biological significance of complement acti-
vation in secretions is not understood. It is possible that the membrane DAF
functions to prevent complement-mediated injury to the epithelial and glandular
cells in a fashion similar to its postulated role in cells found in the vascular space.
Alternatively, it is possible that the epithelial and glandular cell DAF could have
some other, noncomplement-related activity.
Our finding that in skin,joints, and uterus, DAF isassociated with fibrils raises
a number of questions. No staining in blood vessel walls, in cartilage, or of
reticular or elastic fibers occurred. The staining pattern followed that oftype I
collagen fibers onsections counter-stained with Giemsa orToluidine Blue, raising
the possibility that the DAF-positive fibrils may contain type I collagens, which
in different tissues are related but not identical (27). We cannot exclude the
possibility that the staining represents a spurious crossreaction, although this is
unlikely because various mAbs reacting with different DAF epitopes gave iden-
tical results. Interestingly, asymmetric forms of acety1cholinesterase (ACNE), a
protein that is structurally related to DAF (see below), are associated with the
extracellular matrix at neuromuscular junctions and in fish electric organs. In
Disopyge tchudii electric organ, an asymmetric form of ACNE consisting of 12
catalytic subunits attached to a triple helical collagen-like tail is anchored non-
covalently to the extracellular matrix through a linkage that appears to involve
heparin sulfate proteoglycan (29). It is tempting to speculate that the association
of DAF with collagen fibers that contain hydroxyl or amino groups able to
condense with nascent C4b or C3b could serve to reduce the potential for
complement-mediated damage in connective tissues.
The identification of large amounts of DAF antigen in various extracellular
fluids by two-site radioimmunometric assay (Table 1) was surprising. Since
positivity in this assay depends on reactivity with two mAbs directed against
different DAF epitopes, detection of the antigens by this method implied that
they must contain a significant portion of the E''° membrane DAF structure.
Immunoprecipitation of urine DAF with anti-DAF mAbs and Western blot
analysis showed that the antigen migrated with apparent M, 3,000-8,000 smaller
than membrane DAF of E''° (Fig. 3A) and other blood cells (6, 7). The small
difference in apparent size between this extracellular DAF form and blood cell
DAF molecules was associated with a marked difference in hydrophobicity as
shown by its lack ofadsorption to Phenyl-Sepharose and inability to incorporate860
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into membranes (Fig. 3C). The demonstration that urine DAF functioned (Fig.
3C) similarly to the serum regulatory protein, C4bp, indicated that urine DAF
was able to interact with the classical pathway C3-convertase and therefore
contained a DAF functional site. The dissociation of membrane incorporation
and convertase inhibitory activity observed in these studies thus implies that
membrane anchorage and complement regulatory activity in membrane DAF
are mediated by different structures.
Structural studies ofEh° membrane DAF have shown that it is an amphipathic
protein (22, 30). Unlike most membrane proteins that contain polypeptide
membrane anchors consisting ofhydrophobic amino acids, Eh° membrane DAF
possesses a glycolipid membrane anchor. This unconventional non-amino acid
anchoring structure is linked covalently to the COON-terminusofDAF polypep-
tide and is similar to anchoring structures that recently have been described in
(membrane form) variant surface glycoproteins (mfVSGs) o£ trypanosome (31,
32) of leishmania (33) parasites, murine thymocyte Thy-1 antigen (34, 35), and
Eh' AChE (36-38). It is composed of an oligosaccharide, containing ethanolam-
ine(s) and nonacetylated-glucosamine, that is attached through the glucosamine
glycosidic bond to a phospholipid composed ofinositol and fatty acids (22). The
fatty acids are inserted in the cell lipid bilayer and permit lateral mobility of the
attached protein. The phospholipid can be partially cleaved by phosphatidylino-
sitol-specific phospholipase-C (PI-PLC) (30, 22, 39). This cleavage releases mem-
brane DAF from cells and generates a hydrophilic DAF derivative of slightly
reduced apparent M,. similar to urine DAF.
Our studies with foreskin epithelium and HeLa cells (Fig. 4B) verified that
epithelial cells synthesize membrane DAF and additionally showed that this cell
type releases a DAF form into cell culture supernatants (Fig. 5). Analysis of the
released DAF molecule showed that it was ^-5,000 smaller in apparent M,. than
epithelial cell membrane DAF and similar in mobility on gelsto urine DAF. This
finding suggests that urine DAF may be synthesized by the adjacent urethelium.
Other extracellular DAF formscould likewise be generatedbyadjoiningepithelia
and/or glandular cells. The soluble DAF forms could be products of different
genes than those that encode membrane DAF molecules, or could arise from
alternative processing of DAF mRNA occurring after transcription resulting in
secreted rather than membrane forms. Studies with VSGs and Thy-I antigen
have shown that thecDNAs that code for theseproteins predict COON-terminal
extension peptides of 15-31 amino acids that are not found in the mature
proteins (40, 41). There is evidence from biosynthetic studies with VSGs, that
the missing COOH-terminal peptide is excised and replaced with the mfVSG
glycolipid anchor immediately after formation of VSG polypeptide on ribosomes
(42, 43). Consistent with this notion, studies of DAFbiosynthesis (22) have shown
that anchor components are associated with 48 kD pro-DAF before processing
of pro-DAF in the Golgi. The lack of incorporation of the membrane DAF
glycolipid or the attachment ofa different moiety to the DAF COOH-terminus
could result in a soluble DAF form. Alternatively, the soluble DAF species could
derive from membrane DAF molecules themselves. Soluble forms of VSGs,
termed sVSGs, can be isolated from trypanosome cultures (31). The sVSGs
resemble urine DAF in that they are similar in M, to the corresponding mfVSGsWe thank Tom Taylor for photographic assistance, Dr. Milton Singer and the Oregon
Eye Bank for providing corneas, andJanice Gresh for manuscript preparation.
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and markedly less hydrophobic. They have been shown to arise via the action of
an endogenous PI-PLC present in trypanosome membranes (reviewed in refer-
ences 44 and 45). Structural analyses of the soluble DAF forms for components
of the membrane DAF glycolipid anchor proximal to the known site of PI-PLC
cleavage could clarify whether the soluble DAF forms arise by a similar mecha-
nism.
Summary
Decay-accelerating factor (DAF) is a 70 kD membrane regulatory protein that
prevents the activation of autologous complement on cell surfaces. Using im-
munohistochemical methods and a radioimmunometric assay based on mAbs to
DAF, we found large amounts of membrane-associated DAF antigen on the
epithelial surface of cornea, conjunctiva, oral and gastrointestinal mucosa, exo-
crine glands, renal tubules, ureter and bladder, cervical and uterine mucosa, and
pleural, pericardial and synovial serosa. Additionally, we detected soluble DAF
antigen in plasma, tears, saliva, and urine, as well as in synovial and cerebrospinal
fluids. While plasma, tear, and saliva DAF are larger than erythrocyte (Eh°)
membrane DAF by Western blot analysis, urine DAF is slightly smaller (67,000)
in M,. Unlike purified Pu DAF, however, urine DAF is unable to incorporate
into the membrane of red cells. Although its inhibitory activity on the comple-
ment enzyme C3-convertase is lower than that of Eh° DAF, it is comparable to
that of serum C4 binding protein (C4bp). Biosynthetic studies using cultured
foreskin epithelium and Hela cellsdisclosed DAF levels (-2 x 105 molecules/cell)
exceeding those on blood cells. In addition, these studies revealed the synthesis
of two DAF species, one with apparent M,. corresponding to that of epithelial
cell membrane DAF and the other to urine DAF, suggesting that the urine DAF
variant arises from adjacent epithelium. The function of DAF in body fluids is
unknown, butthe observation that urine DAF has C4bp-(or factor H-)likeactivity
shows that it could inhibit the fluid phase activation of the cascade.
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